Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 735-742

  Luo, Pei ^a   Wong, Yuen Fan ^a   Ge, Lin ^a   Zhang, Zhi Feng ^b   Liu, Yuan ^b   Liu, Liang ^a   Zhou, Hua ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b SOUTHWEST UNIVERSITY FOR NATIONALITIES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; BRADYKININ; CARRAGEENAN; CYCLOOXYGENASE 2; HISTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PLUMBAGIN; PROSTAGLANDIN E2; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; MALE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

ABDOMINAL PAIN; ACETIC ACID; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; CARRAGEENAN; CYCLOOXYGENASE 2; DINOPROSTONE; EDEMA; FOOT; GENE EXPRESSION; HISTAMINE; HOT TEMPERATURE; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MAGNESIUM SULFATE; MALE; MICE; MICE, INBRED ICR; NAPHTHOQUINONES; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; PAIN THRESHOLD; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649591458     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.170852     Document Type: Article

References (40)

1. Aggarwal BB (2004) Nuclear factor-κB: the enemy within. Cancer Cell 6:203-208.
2. Appleby SB, Ristimäki A, Neilson K, Narko K, and Hla T (1994) Structure of the human cyclo-oxygenase-2 gene. Biochem J 302:723-727.
3. Baeuerle PA and Baltimore D (1996) NF-κB: ten years after. Cell 87:13-20.
4. Bogdan C (2001) Nitric oxide and the immune response. Nat Immunol 2:907-916.
5. Collart MA, Baeuerle P, and Vassalli P (1990) Regulation of tumor necrosis factor α transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 10:1498-1506. (Pubitemid 20105021)
6. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, and Subbaramaiah K (2001) Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2:544-551. (Pubitemid 33586867)
7. Devi PU, Rao BS, and Solomon FE (1998) Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. Indian J Exp Biol 36:891-895. (Pubitemid 28417163)
8. Dewey WL, Harris LS, Howes JF, and Nuite JA (1970) The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J Pharmacol Exp Ther 175:435-442.
9. Ding Y, Chen ZJ, Liu S, Che D, Vetter M, and Chang CH (2005) Inhibition of Nox-4 activity by plumbagin, a plant-derived bioactive naphthoquinone. J Pharm Pharmacol 57:111-116.
10. Ducut Sigala JL, Bottero V, Young DB, Shevchenko A, Mercurio F, and Verma IM (2004) Activation of transcription factor NF-κB requires ELKS, an IκB kinase regulatory subunit. Science 304:1963-1967.
11. Fields HL (1987) Analgesic Drugs. MacGraw-Hill, New York.
12. Fukawa K, Kawano O, Hibi M, Misaki N, Ohba S, and Hatanaka Y (1980) A method for evaluating analgesic agents in rats. J Pharmacol Methods 4:251-259.
13. Gyires K and Torma Z (1984) The use of the writhing test in mice for screening different types of analgesics. Arch Int Pharmacodyn 267:131-140.
14. Harris SG, Padilla J, Koumas L, Ray D, and Phipps RP (2002) Prostaglandins as modulators of immunity. Trends Immunol 23:144-150.
15. Jaiswal AS, Bloom LB, and Narayan S (2002) Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1. Oncogene 21:5912-5922.
16. Mollace V, Muscoli C, Masini E, Cuzzocrea S, and Salvemini D (2005) Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57:217-252.
17. Ozaki Y (1990) Anti-inflammatory effects of Curcuma xanthorrhiza Roxb, and its active principles. Chem Pharm Bull 38:1045-1048.
18. Prasad VS, Devi PU, Rao BS, and Kamath R (1996) Radiosensitizing effect of plumbagin on mouse melanoma cells grown in vitro. Indian J Exp Biol 34:857-858.
19. Raj PP (1996) Pain Mechanisms: A Comprehensive Review. Mosby Year Book, St. Louis, MO.
20. Ruetten H and Thiemermann C (1997) Effect of calpain inhibitor I, an inhibitor of the proteolysis of IκB, on the circulatory failure and multiple organ dysfunction caused by endotoxin in the rat. Br J Pharmacol 121:695-704. (Pubitemid 27260772)
21. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT, and Currie MG (1996) Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118:829-838.
22. Sandur SK, Ichikawa H, Sethi G, Ahn KS, and Aggarwal BB (2006) Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-κB activation and NF-κB-regulated gene products through modulation of p65 and IκBα kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. J Biol Chem 281:17023-17033.
23. Schmidt AP, Böhmer AE, Antunes C, Schallenberger C, Porciú ncula LO, Elisabetsky E, Lara DR, and Souza DO (2009) Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol 156:163-172.
24. Sheeja E, Joshi SB, and Jain DC (2010) Bioassay-guided isolation of antiinflammatory and antinociceptive compound from Plumbago zeylanica leaf. Pharm Biol 48:381-387.
25. Siegmund E, Cadmus R, and Lu G (1957) A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med 95:729-731.
26. Singh UV and Udupa N (1997) Reduced toxicity and enhanced antitumor efficacy of β-cyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. Indian J Physiol Pharmacol 41:171-175.
27. Sonis ST (2002) The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13:380-389.
28. Srinivas P, Gopinath G, Banerji A, Dinakar A, and Srinivas G (2004) Plumbagin induces reactive oxygen species, which mediate apoptosis in human cervical cancer cells. Mol Carcinog 40:201-211.
29. Sugie S, Okamoto K, Rahman KM, Tanaka T, Kawai K, Yamahara J, and Mori H (1998) Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett 127:177-183.
30. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, and Lee SS (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation. Mutat Res 480:243-268.
31. Tak PP and Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7-11.
32. Tracey KJ and Cerami A (1993) Tumor necrosis factor: an updated review of its biology. Crit Care Med 21:S415-S422.
33. Vane JR and Botting RM (1998) Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47 (Suppl 2):S78-S87.
34. Vinegar R, Truax JF, Selph JL, Johnston PR, Venable AL, and McKenzie KK (1987) Pathway to carrageenan-induced inflammation in the hind limb of the rat. Fed Proc 46:118-126.
35. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, and Chen ZJ (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412:346-351.
36. Wang CC, Chiang YM, Sung SC, Hsu YL, Chang JK, and Kuo PL (2008) Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett 259:82-98.
37. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, and Sitaraman SV (2003) IL-6 induces NF-κB activation in the intestinal epithelia. J Immunol 171:3194-3201.
38. Won JH, Im HT, Kim YH, Yun KJ, Park HJ, Choi JW, and Lee KT (2006) Antiinflammatory effect of buddlejasaponin IV through the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via the NF-κB inactivation. Br J Pharmacol 148:216-225.
39. Xie QW, Kashiwabara Y, and Nathan C (1994) Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 269:4705-4708.
40. Zhou H, Wong YF, Cai X, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, and Liu L (2006) Suppressive effects of JCICM-6, the extract of an anti-arthritic herbal formula, on the experimental inflammatory and nociceptive models in rodents. Biol Pharm Bull 29:253-260.